NTHI NeOnc Technologies Holdings Inc.

NEO212 enters its next regulatory milestone with Phase 1 dose escalation completed and 610 mg selected as the recommended Phase 2 dose. Clinical observations reported to date include approximately 60% tumor reduction followed by 21 months of disease control in one recurrent GBM patient, and approximately 16 months of stable disease in a patient with brain metastases. While individual cases do not establish efficacy, these observations provide important clinical context as we prepare for the November 17 FDA meeting and the next stage of NEO212’s development. $NTHI $NVAX $RXRX

$NTHI In clinical-stage biotech, value is built by turning scientific potential into evidence that can move a program forward. That’s what makes NEO100’s Phase 2a results important for $NTHI. The study reported 26.09 months median overall survival in recurrent IDH1-mutant high-grade glioma, alongside 48.9% six-month progression-free survival versus a 20% historical benchmark. Those results give NeOnc clinical evidence to build on as NEO100 moves toward its next regulatory stage—bringing the program one step further along the path from scientific potential to a more advanced clinical asset. $NTHI $IOVA $CRSP

$NTHI — NeOnc has several things happening at once. NEO100 produced positive Phase 2a results in recurrent malignant glioma, management recently raised $15M, and the company has now scheduled an FDA End-of-Phase 1 meeting for NEO212. That FDA discussion should help determine the next clinical-development steps

NeOnc is entering its next stage with clinical progress, additional capital, and a clearer path forward. Following positive NEO100 Phase 2a results, the Company completed a $15M financing as NEO100 advances toward its next regulatory steps. NEO212 has also completed Phase 1 dose escalation and established a recommended Phase 2 dose. Against this backdrop, senior leadership has invested approximately $629K in 160,016 $NTHI shares since the Phase 2a results using personal funds. As Amir Heshmatpour stated, his investment reflects his commitment to NeOnc's mission, its patients, and the long-term value being built alongside shareholders. $NTHI

NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution $NTHI https://stocktwits.com/news/others/business/ne-onc-technologies-redeems-all-outstanding-series-a-convertible-preferred-stock-and-eliminates-related-potential-dilution/cZtrowURB56

NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results $NTHI https://stocktwits.com/news/others/business/ne-onc-executives-invest-approximately-629-000-in-open-market-stock-purchases-following-positive-neo-100-phase-2a-results/cZtYKWdRB2y

$NTHI reported encouraging Phase 2a survival data for intranasal NEO100 in recurrent high-grade glioma, showing median OS of 26.1 months.

$NTHI huge insider confidence and offering closed.at much higher.prices. warrants at 4.2